NYXH
Nyxoah
NASDAQ: NYXH · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$3.33
+0.35% today
Updated 2026-06-04
Market cap
$64.81M
P/E ratio
—
P/S ratio
4.23x
EPS (TTM)
$-2.48
Dividend yield
—
52W range
$1 – $9
Volume
0.0M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A3.0
Quality
D2.5
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-5.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$8.90
+167.27%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 498.90% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -5.42 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-22.36M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $3.08M | $4.35M | $4.52M | $10.02M | $15.33M |
| Net income | $-31.23M | $-43.21M | $-59.24M | $-90.08M | $-18.42M |
| EPS | — | — | — | — | $-2.48 |
| Free cash flow | $-45.10M | $-55.74M | $-55.30M | $-68.30M | $-22.36M |
| Profit margin | -1,012.48% | -993.84% | -1,310.24% | -899.05% | — |
Peer comparison
Smart narrative
Nyxoah trades at $3.33. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -5.42, it sits in the distress. TTM revenue stands at $15.33M.
Frequently asked questions
What is Nyxoah's stock price?
Nyxoah (NYXH) trades at $3.33, on a P/S of 4.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Nyxoah overvalued?
Nyxoah carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Nyxoah (NYXH)?
The 12-month analyst consensus target is $8.90, about 167.3% above the current $3.33. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Nyxoah's revenue?
Nyxoah's trailing twelve-month revenue is $15.33M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Nyxoah's Altman Z-Score is -5.42, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.23x
ROE-169.02%
Beta0.89
50D MA$3.05
200D MA$4.46
Shares out0.04B
Float0.02B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—